Biosimilars and emerging modalities using novel diol-linked size exclusion columns
Dr. Helen Whitby explores the applicability of the new diol-link size exclusion column, bioZen dSEC-2, for the effective analysis of biosimilars, antibody–drug conjugates (ADCs) and oligonucleotides.